×
ASH 2020 Annual Meeting and Exposition
https://www.hematology.org/meetings/annual-meeting

Attend the world’s most comprehensive hematology event of the year for invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.

ASH 2020 Schedule and Program
https://www.hematology.org/meetings/annual-meeting/schedule-and-program

The final program, personal scheduler, oral and poster sessions, scientific program, education program, general sessions, special-interest sessions, trainee activities, policy and practice, global capacity-building showcase, acknowledgments, related content

Associations between hematology/oncology fellows' training and mentorship experiences a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855099
Blood Advances; Masselink LE, Erikson CE et. al.

Nov 7th, 2019 - As the adult hematology and oncology fellowship training pathways have merged in the United States and concerns have arisen about the aging of practicing hematologists, the American Society of Hematology and hematology education leaders are looking to improve their understanding of the factors that contribute to fellows' plans to enter hematology-only careers. With the support of the American S...

Teetering on a liver's edge: a case report highlighting clinical decision-making in thr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836470
BMC Cancer; Yan A, Erdman L et. al.

Nov 6th, 2019 - This report illustrates the importance of a detailed history and physical exam and careful analysis of hematologic parameters when diagnosing ITP. This case demonstrates that even with subtle deviations from typical ITP findings one must promptly reevaluate the diagnosis. This case also highlights the importance of peripheral smear review by an expert in pediatric hematopathology. A previously ...

Remembering Thomas P. Stossel, CPRIT Awards $136 Million in 71 New Grants, and more
https://www.ashclinicalnews.org/news/the-society-pages/remembering-thomas-p-stossel-cprit-awards-136-million-71-new-grants/

Nov 1st, 2019 - Remembering Thomas P. Stossel (1941 – 2019) Thomas P. Stossel, MD, former president of the American Society of Hematology (ASH), passed away unexpectedly on September 29. Born in Chicago in 1941, Dr. Stossel grew up in Wilmette, Illinois. He attended Princeton University and Harvard Medical School before completing his internal medicine training at Massachusetts General Hospital and his hematol...

ASH Announces Three New Executive Committee Members, Free Childcare at the 2019 ASH Annual Meeting, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-announces-three-new-executive-committee-members-free-childcare-2019-ash-annual-meeting/

Nov 1st, 2019 - Jane N. Winter, MD, Vice President Alison Loren, MD, Councillor Bob Löwenberg, MD, PhD, Councillor Congratulations to ASH’s Three New Executive Committee Members The American Society of Hematology (ASH) has announced the election of three new members to its Executive Committee for terms beginning after the 2019 ASH Annual Meeting in December. Jane N. Winter, MD, will serve a one-year term as vi...

ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline R...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849945
Blood Advances; Luo X, Feurstein S et. al.

Oct 27th, 2019 - Standardized variant curation is essential for clinical care recommendations for patients with inherited disorders. Clinical Genome Resource (ClinGen) variant curation expert panels are developing disease-associated gene specifications using the 2015 American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines to reduce curation discrepancies...

Zanetta Lamar, MD, Joins Florida Cancer Specialists
https://ascopost.com/issues/october-25-2019/zanetta-lamar-md-joins-florida-cancer-specialists/

Oct 24th, 2019 - Florida Cancer Specialists & Research Institute (FCS) welcomes Zanetta Lamar, MD, to the statewide practice. She is practicing medical oncology and hematology in the Naples Goodlette office. Zanetta Lamar, MD After earning her medical degree with honors from Meharry Medical College in Nashville, Dr. -Lamar completed her internal medicine internship and residency, as well as her hematology and o...

Metabolomic profiling identifies pathways associated with minimal residual disease in c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838385
EBioMedicine Schraw JM, Junco JJ et. al.

Oct 21st, 2019 - End-induction minimal residual disease (MRD) is the strongest predictor of relapse in paediatric acute lymphoblastic leukaemia (ALL), but an understanding of the biological pathways underlying early treatment response remains elusive. We hypothesized that metabolomic profiling of diagnostic bone marrow plasma could provide insights into the underlying biology of early treatment response and inf...

Pulmonary Embolism (PE) Guidelines
https://emedicine.medscape.com/article/300901-guidelines

Oct 15th, 2019 - Guidelines Summary Guidelines for the diagnosis and management of pulmonary embolism (PE) have been issued by the following organizations: American Academy of Family Physicians (AAFP)/American College of Physicians (ACP) [4] American College of Physicians (ACP) [111] American College of Emergency Physicians (ACEP) [112] American College of Radiology (ACR) [69] American College of Chest Physicia...

Venous Thromboembolism (VTE) Workup
https://emedicine.medscape.com/article/1267714-workup

Oct 14th, 2019 - Approach Considerations Diagnosis of venous thromboembolism (VTE) may include laboratory tests, imaging (eg, chest radiography, computed tomography [CT], angiography, ultrasonography [US], echocardiography, and ventilation-perfusion [V/Q] scanning) and tests such as plethysmography and electrocardiography (ECG). Guidelines for diagnosis of VTE have been published by the American Society of Hema...

Xarelto OK'd for VTE Prevention in Acute Medical Illness
https://www.medpagetoday.com/cardiology/venousthrombosis/82720

Oct 14th, 2019 - The FDA approved rivaroxaban (Xarelto) to prevent venous thromboembolism (VTE) and related deaths for at-risk acutely ill medical patients not at high risk of bleeding, Janssen announced Monday. The approval was for the hospitalization and through discharge to a total recommended duration of 31 to 39 days. "Rather than facing daily injections with older anticoagulants, patients now have a new o...

Inhaled nitric oxide for treating pain crises in people with sickle cell disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788324
The Cochrane Database of Systematic Reviews; Aboursheid T, Albaroudi O et. al.

Oct 11th, 2019 - In people with sickle cell disease, sickled red blood cells cause the occlusion of small blood vessels which presents as episodes of severe pain known as pain crises or vaso-occlusive crises. The pain can occur in the bones, chest, or other parts of the body, and may last several hours to days. Pain relief during crises includes both pharmacologic and non-pharmacologic treatments. The efficacy ...

Anemia management in cancer patients with chronic kidney disease.
https://doi.org/10.1111/sdi.12841
Seminars in Dialysis REFERENCES; Latcha S

Oct 9th, 2019 - Cancer and kidney disease are linked by causality and comorbidities. Observational data show an increased risk of malignancy as renal function declines. Erythropoietin stimulating agents (ESAs), which are the cornerstone therapy for anemia patients with chronic kidney disease and cancer, are associated with increased risks for cancer, cancer-related mortality, progression of disease, and thromb...

Hypertension & CV Adverse Events With Ibrutinib in 'Real World'
https://www.medscape.com/viewarticle/919574

Oct 7th, 2019 - Since its approval in 2016, ibrutinib (Imbruvica, Pharmacyclics) has rapidly changed the treatment landscape of chronic lymphocytic leukemia (CLL) and several rarer hematologic malignancies. However, emerging real-world data are now suggesting caution, owing to increased risk for hypertension and other cardiovascular adverse events. A study published online October 3 in Blood reported a retrosp...

ASH Clinical News Now Available on the ASH Publications App, ABIM Changing Maintenance of Certification Standards, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-clinical-news-now-available-ash-publications-app-abim-changing-maintenance-certification-standards/

Oct 1st, 2019 - ASH Clinical News Now Available on the ASH Publications App The American Society of Hematology (ASH) Publications app provides access to content from Blood, Blood Advances, The Hematologist, and, now, ASH Clinical News, plus great features that allow readers to: Save articles for offline reading Take notes on specific articles Access Blood articles ahead of publication with First Edition Get no...

Remembering Stanley Schrier, John Hansen, and more
https://www.ashclinicalnews.org/news/the-society-pages/remembering-stanley-schrier-john-hansen/

Oct 1st, 2019 - Stanley Schrier, MD Remembering Stanley Schrier (1929 – 2019) Stanley Schrier, MD, a former American Society of Hematology (ASH) president who spent nearly 60 years at Stanford University’s Department of Medicine, passed away on August 16. In 1954, Dr. Schrier graduated from Johns Hopkins University School of Medicine, where he remained for his internship before moving to the universities of Mi...

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545304
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting.|2019||therapeutic use,therapeutic use,therapeutic use,therapy,drug therapy,therapy,therapy,

Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545307
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.|2019||adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,therapy,drug therapy,genetics,therapy,adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545309
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting.|2019||therapeutic use,drug therapy,therapeutic use,adverse effects,therapeutic use,drug therapy,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,therapeutic use,

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545305
Clinical Advances in Hematology & Oncology : H&O; Haverkos B

Sep 22nd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A hematologist's perspective.|2019|Haverkos B,|

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545306
Clinical Advances in Hematology & Oncology : H&O; Geskin LJ

Sep 22nd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A dermatologist's perspective.|2019|Geskin LJ,|

Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545308
Clinical Advances in Hematology & Oncology : H&O; O'Brien SM

Sep 22nd, 2019 - Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting: commentary.|2019|O'Brien SM,|

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545310
Clinical Advances in Hematology & Oncology : H&O; Mesa RA

Sep 22nd, 2019 - Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting: commentary.|2019|Mesa RA,|

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942175
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation; Holstein SA, Al-Kadhimi Z et. al.

Sep 18th, 2019 - The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discus...

Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas
https://ascopost.com/issues/september-10-2019/update-on-fda-approved-car-t-cell-gene-therapy-for-b-cell-lymphomas/

Sep 9th, 2019 - Syed Ali Abutalib, MD David L. Porter, MD On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, primary...

Valoctocogene Roxaparvovec Continues to Improve Bleeding Outcomes in Patients with Hemophilia A
https://www.ashclinicalnews.org/on-location/other-meetings/valoctocogene-roxaparvovec-continues-improve-bleeding-outcomes-patients-hemophilia/

Sep 1st, 2019 - In three-year follow-up results from an ongoing phase I/II study of patients with hemophilia A, valoctocogene roxaparvovec gene therapy significantly reduced annual bleeding rates (ABRs) and increased factor VIII (FVIII) activity levels. Lead author John Pasi, MBChB, PhD, from Barts and the London School of Medicine and Dentistry, presented the findings at the 2019 Congress of the International...

ASH Sickle Cell Initiative Wins Top ASAE Prize, ASH-a-Palooza 2019 Announced, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-sickle-cell-initiative-wins-top-asae-prize-ash-palooza-2019-announced/

Sep 1st, 2019 - ASH Sickle Cell Disease Initiative Wins Top ASAE Prize The American Society of Hematology (ASH) is proud to have been named a 2019 Power of A Summit Award winner for the Society’s multifaceted Sickle Cell Disease (SCD) Initiative. The Power of A Summit Award, given annually by the American Society of Association Executives (ASAE), recognizes the association community’s valuable contributions on...

ABIM: Self-paced MOC pathway under development
https://www.mdedge.com/internalmedicine/article/207353/business-medicine/abim-self-paced-moc-pathway-under-development/page/0/1?channel=27980

Aug 31st, 2019 - Alan Lichtin, MD, chair of the MOC working group for the American Society of Hematology (ASH), said the self-paced pathway is a much-needed option, particularly the immediate feedback on test questions. “For years, ASH has been advocating that ABIM move from the traditional sit-down testing to an alternative form of ‘formative’ assessment that has been adapted by other specialty boards,” Dr.

CMS Expands Access to CAR T-Cell Therapies Nationwide
https://www.ashclinicalnews.org/online-exclusives/cms-expands-access-car-t-cell-therapies-nationwide/

Aug 16th, 2019 - The Centers for Medicare and Medicaid Services (CMS) will now provide “consistent and predictable” nationwide access to chimeric antigen receptor (CAR) T-cell therapies, according to CMS Administrator Seema Verma. This decision comes in the wake of last week’s announcement that CMS was increasing payments for CAR T-cell therapies from 50 percent to 65 percent. Prior to this announcement, Medica...

Highlights in Geriatric Hematology From the ASH Annual Meeting & Exposition
https://ascopost.com/issues/august-10-2019/highlights-in-geriatric-hematology-from-the-ash-annual-meeting-exposition/

Aug 9th, 2019 - GUEST EDITOR Stuart M. Lichtman, MD, FACP, FASCO Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and Professor of Medicine at Weill Cornell Medical College, New York....

ASH Honors Richard Aster, MD, With the Wallace H. Coulter Award for Lifetime Achievement in Hematology
https://ascopost.com/issues/august-10-2019/ash-honors-richard-aster-md/

Aug 9th, 2019 - Richard Aster, MD The American Society of Hematology (ASH) will recognize Richard Aster, MD, of the Medical College of Wisconsin and Versiti Blood Center of Wisconsin in Milwaukee with the 2019 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Aster will be honored for his significant contributions to hematology through research, mentorship, and education throughout his 62-ye...

CMS Increases Payment, Access to CAR T-Cell Therapy
https://www.ashclinicalnews.org/online-exclusives/medicare-increases-payments-car-t-cell-therapy/

Aug 9th, 2019 - The Centers for Medicare and Medicaid Services (CMS) announced two policy changes that should improve access to chimeric antigen receptor (CAR) T-cell therapies: First, the agency issued a final rule that raises payments for new technologies, including CAR T-cell therapies, from 50% to 65%. Next, CMS Administrator Seema Verma said that CMS will now provide “consistent and predictable” nationwid...

Treatment of Pediatric Venous Thromboembolism.
https://doi.org/10.12788/jhm.3246
Journal of Hospital Medicine; Meier KA, Tarango C

Aug 6th, 2019 - American Society of Hematology 2018 Guidelines for the management of venous thromboembolism: treatment of pediatric venous thromboembolism DEVELOPER: The American Society of Hematology multidisciplinary subcommittee RELEASE DATE: November 27, 2018 FUNDING SOURCE: American Society of Hematology PRIOR VERSION: N/A TARGET POPULATION: less than 18 years of age.

ASH Backs Palliative Blood Transfusions During Hospice Care, Announces 2019 Honorific and Mentor Award Recipients, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-backs-palliative-blood-transfusions-hospice-care-announces-2019-honorific-mentor-award-recipients/

Aug 1st, 2019 - ASH Backs the Use of Palliative Blood Transfusions During Hospice Care for Symptom Improvement The American Society of Hematology (ASH) has announced its support of palliative blood transfusions during end-of-life care in a recent policy statement. The Medicare hospice benefit for patients undergoing end-of-life care focuses on maximizing quality of life by providing comfort and support service...

ICYMI: Ibrutinib/rituximab combo improves CLL survival
https://www.mdedge.com/hematology-oncology/article/205472/cll/icymi-ibrutinib/rituximab-combo-improves-cll-survival?channel=59374
Lucas Franki

Jul 31st, 2019 - Patients with previously untreated chronic lymphocytic leukemia (CLL) aged 70 years or younger who received ibrutinib/rituximab therapy experienced significantly greater progression-free survival, compared with those who received standard chemotherapy with fludarabine, cyclophosphamide, and rituximab (89. 4% vs.

Tumour flare reaction in cancer treatments: a comprehensive literature review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749970
Anti-cancer Drugs; Taleb B A

Jul 27th, 2019 - In the past decade, tumour flare reaction (TFR) was considered as a new side effect associated with immunomodulatory agents (IMiDs) and as a condition of chronic lymphocytic leukaemia (CLL). However, this phenomenon is also observed with immune checkpoint inhibitors in solid tumours. It is still poorly understood and its incidence is underestimated. TFR has been associated with morbidity, there...

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
https://ascopost.com/issues/july-25-2019/fda-approves-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma/

Jul 24th, 2019 - On June 27, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The application received approval through the FDA’s Real-Time Oncology Review pilot program. The approval is based on results f...

New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more
https://www.ashclinicalnews.org/news/ash-directions/new-ash-congressional-fellow-accepting-submissions-2019-ash-annual-meeting/

Jul 1st, 2019 - Zachary Kiser, PhD Next ASH Congressional Fellow Is Bound for Capitol Hill Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the next ASH Congressional Fellow. Dr. Kiser, a post-doctoral fellow in the National Institutes of Health–funded Research Program at the University of Minnesota, will spend the 2019-2020 academic year in Washington, D.C., where he wil...

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma
https://ascopost.com/News/60199

Jun 26th, 2019 - Today, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The application received approval through the FDA’s Real-Time Oncology Review pilot program. The approval is based on results from t...

The use of direct oral anticoagulants for extended duration thromboprophylaxis in medic...
https://doi.org/10.1007/s11239-019-01900-2
Journal of Thrombosis and Thrombolysis; Alshouimi RA, Al Rammah SM et. al.

Jun 21st, 2019 - The extended use of thromboprophylaxis with direct oral anticoagulants (DOACs) for more than 30 days has been evaluated as an alternative for the standard duration thromboprophylaxis (7-10 days) with low molecular weight heparin in medically ill patients to reduce the risk of venous thromboembolism (VTE) after hospital discharge. EMBASE and MEDLINE were searched for studies evaluating extended ...

Selected Abstracts From the 2019 ASCO Annual Meeting
https://ascopost.com/issues/june-10-2019/selected-abstracts-from-the-2019-asco-annual-meeting/

Jun 9th, 2019 - Plasma Cell Dyscrasias Syed Ali Abutalib, MD Ola Landgren, MD, PhD To complement The ASCO Post’s comprehensive coverage of the 2019 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for plasma cell dyscrasias, particularly multiple myeloma. For full details of these study abstracts, visit http://abstracts.asco.org. ABSTR...

Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More
https://www.ashclinicalnews.org/news/the-society-pages/remembering-milton-h-freedman-caryn-lerman-named-director-usc-norris/

Jun 1st, 2019 - Remembering Milton H. Freedman (1919 – 2019) Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21, 2019. Dr. Freedman was born in Atlanta, where he spent almost his entire life, except for a stint in the U.S. Navy as a flight surgeon during World War II and a hematology fellowship at Pratt Diagnostic Hospital (now Tufts Medical Center) in Bost...

Evolving paradigm in thrombophilia screening.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687403
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis; Ashraf N, Visweshwar N et. al.

May 30th, 2019 - : The role of genetic thrombophilia screening for identifying a hypercoagulable state in the management of venous thromboembolism. We searched MEDLINE and EMBASE from 1995 to 2017, the websites of the professional bodies including American Society of Hematology, British Society of Hematology, International Society of Thrombosis and Hemostasis, College of American Pathologists, American College ...

Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-...
https://doi.org/10.1097/PPO.0000000000000379
Cancer Journal (Sudbury, Mass.); Shah UA, Smith EL

May 28th, 2019 - Multiple myeloma is still an incurable malignancy despite the many new therapies approved over the last decade and therefore represents a significant unmet medical need. To address this need, adoptive cellular therapies using chimeric antigen receptor (CAR) T-cells are being explored in clinical investigations. The number of CAR T-cell trials for multiple myeloma has increased exponentially ove...

Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible...
https://doi.org/10.1016/j.clml.2019.04.009
Clinical Lymphoma, Myeloma & Leukemia; Cao Y, Wan N et. al.

May 27th, 2019 - Many new regimens have been applied to newly diagnosed transplant-ineligible multiple myeloma, but no head-to-head research has been performed to compare the efficacy of these treatments. Currently lenalidomide plus dexamethasone (Rd) is one of the standard treatments. Our aim was to make a comparison of these treatments to Rd by a network meta-analysis. We performed a systematic review and net...

Debating the Role of Opioids in the Management of Chronic Cancer Pain
https://ascopost.com/issues/may-25-2019/debating-the-role-of-opioids-in-the-management-of-chronic-cancer-pain/

May 24th, 2019 - A Conversation With Leslie J. Blackhall, MD, and Charles F. von Gunten, MD, PhD Despite the increasing public awareness of the danger of the overuse of prescription opioids, drug overdose deaths continue to rise in the United States. According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2017, nearly 400,000 people died of an overdose involving opioids, including both p...

Charles G. Mullighan, MBBS (Hons), MSc, MD, Named St. Jude Comprehensive Cancer Center Deputy Director
https://ascopost.com/issues/may-25-2019/charles-mullighan-named-st-jude-comprehensive-cancer-center-deputy-director/

May 24th, 2019 - The St. Jude Children’s Research Hospital Comprehensive Cancer Center has appointed Charles G. Mullighan, MBBS (Hons), MSc, MD, as its new Deputy Director. In this new position, Dr. Mullighan will help guide precision medicine and preclinical strategic research initiatives for the Center, which is the nation’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted s...

Erythropoiesis-Stimulating Agents Recommended for Some Patients With Cancer and Anemia
https://ascopost.com/issues/may-25-2019/erythropoiesis-stimulating-agents-recommended-for-some-patients-with-cancer-and-anemia/

May 24th, 2019 - ASCO and the American Society of Hematology (ASH) have released an update to existing guidelines for use of erythropoiesis-stimulating agents to manage anemia in patients with cancer.1 “The current update aims to increase awareness of recent developments regarding the use of erythropoiesis-stimulating agents in patients with cancer. New information has emerged that may not be widely disseminate...

Anjali Mishra, PhD, and Nitin Chakravarti, PhD, Join Sidney Kimmel Cancer Center at Jefferson Health
https://ascopost.com/issues/may-25-2019/staff-join-sidney-kimmel-cancer-center-at-jefferson-health/

May 24th, 2019 - The Sidney Kimmel Cancer Center–Jefferson Health (SKCC) recently welcomed Anjali Mishra, PhD, and Nitin Chakravarti, PhD, to its team of researchers focused on hematologic cancers. Both Drs. Mishra and Chakravarti are Assistant Professors in the Department of Medical Oncology. Dr. Mishra is a cancer biologist studying the pathogenetic mechanisms in cytokine-driven leukemias and lymphomas. Her r...

ASH President Comments on Medicare Proposal for CAR T-Cell Therapy
https://ascopost.com/issues/may-25-2019/ash-president-comments-on-medicare-proposal-for-car-t-cell-therapy/

May 24th, 2019 - Roy Silverstein, MD Recently, the Centers for Medicare & Medicaid Services (CMS) proposed to improve the reimbursement currently given to hospitals that provide chimeric antigen receptor (CAR) T-cell therapy to patients with blood cancer as part of the Fiscal Year 2020 Inpatient Prospective Payment System proposed rule. American Society of Hematology (ASH) President Roy Silverstein, MD, of the ...

Expert Point of View: Irene Ghobrial, MD, and Monica M. Bertagnolli, MD, FACS, FASCO
https://ascopost.com/issues/may-25-2019/epov-irene-ghobrial-and-monica-bertagnolli/

May 24th, 2019 - Irene Ghobrial, MD Irene Ghobrial, MD, of Dana-Farber Cancer Institute and Harvard Medical School, Boston, who has conducted seminal trials in smoldering myeloma, commented on the phase III E3A06 study. Asked by The ASCO Post whether E3A06 settles the issue of treating smoldering disease, Dr. Ghobrial responded, “Yes, and no.” “Yes, because this is the first well-randomized phase III trial in t...

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeti...
https://doi.org/10.1016/j.clml.2019.03.008
Clinical Lymphoma, Myeloma & Leukemia; Terpos E, Ntanasis-Stathopoulos I et. al.

May 11th, 2019 - Herein, we summarize the novel clinical data for multiple myeloma (MM) that were presented in the 2019 Annual Meeting of the American Society of Hematology. Triplet regimens including lenalidomide-dexamethasone for high-risk smoldering MM are effective but longer follow-up data are needed. Among transplant-eligible, newly diagnosed MM (NDMM) patients, carfilzomib- and daratumumab-based combinat...

CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain
https://ascopost.com/issues/may-10-2019/cdc-issues-clarification-on-guideline-for-prescribing-opioids-for-chronic-pain/

May 9th, 2019 - ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) recently acknowledged receipt of a key clarification1 from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. The clarification regarding the CDC’s Guideline for Prescribing Opioids for Chronic Pain2 came as a result of a collabo...

Hematologist Francesco Lo Coco, MD, Dies in Rome at 63
https://ascopost.com/issues/may-10-2019/francesco-lo-coco-dies-in-rome-at-63/

May 9th, 2019 - Francesco Lo Coco, MD Hematologist Francesco Lo Coco, MD, known for his research accomplishments in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL), died in Rome on March 3, 2019. He was 63. After graduating from the Medical School in Pisa, he moved to La Sapienza University of Rome in 1981. From 1992 to 1994, Dr. Lo Coco was a visiting researcher at the Institute for C...

CMS proposes payment increase for administering CAR T in the hospital
https://www.mdedge.com/hematology-oncology/article/200156/practice-management/cms-proposes-payment-increase-administering?channel=39313
Alicia Gallegos

May 3rd, 2019 - Hospitals could get a payment bump for administering chimeric antigen receptor (CAR) T-cell therapies under a proposed rule issued by the Centers for Medicare & Medicaid Services. Penn Medicine CAR T cells ready for infusion The proposal calls for raising the new technology add-on payment (NTAP) associated with the therapies from 50% of the technology to 65%, an increase from $186,500 to $242,4.

Training curriculum to help patient representatives participate meaningfully in the dev...
https://doi.org/10.1136/bmjebm-2019-111186
BMJ Evidence-based Medicine; Daraz L, Webb S et. al.

May 1st, 2019 - Patient participation in the development of clinical practice guidelines (CPGs) is critical for validity and trust. Many guideline panels now include patient representatives. Engagement of these individuals may be improved by training them about the process and their role before they join a guideline panel. To aid patient representatives in engagement in the improvement of guidelines, we develo...

Biomedical Research Community Concerned About Cuts in Proposed 2020 Budget
https://www.ashclinicalnews.org/news/proposed-2020-budget-slash-cancer-funding/

May 1st, 2019 - On March 11, President Donald Trump released his proposed fiscal year 2020 budget, called “A Budget for a Better America,” that includes a substantial 12-percent cut to funding for the U.S. Department of Health and Human Services (HHS). This amounts to a $4.7-billion decrease in funding for the National Institutes of Health (NIH) – the U.S.’s largest provider of funding for biomedical research....

Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematolo...
https://www.ncbi.nlm.nih.gov/pubmed/32720925
Clinical Advances in Hematology & Oncology : H&O;

Apr 30th, 2019 - Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting.|2019||

Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematolo...
https://www.ncbi.nlm.nih.gov/pubmed/32720926
Clinical Advances in Hematology & Oncology : H&O; Locke FL

Apr 30th, 2019 - Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting: Commentary.|2019|Locke FL,|

New CMS Hospital Rule Seeks More Pay for CAR-T, Some Devices
https://www.staging.medscape.com/viewarticle/912218

Apr 24th, 2019 - The Centers for Medicare & Medicaid Services (CMS) is proposing, through a new Medicare hospital payment rule, to provide extra money for certain newer medical products, including costly bioengineered chimeric antigen receptor T-cell (CAR-T) treatments for blood cancers. CMS on Tuesday released the draft fiscal 2020 Inpatient Prospective Payment System rule, which would increase reimbursement f...

New CMS Hospital Rule Seeks More Pay for CAR-T, Some Devices
https://www.medscape.com/viewarticle/912218

Apr 24th, 2019 - The Centers for Medicare & Medicaid Services (CMS) is proposing, through a new Medicare hospital payment rule, to provide extra money for certain newer medical products, including costly bioengineered chimeric antigen receptor T-cell (CAR-T) treatments for blood cancers. CMS on Tuesday released the draft fiscal 2020 Inpatient Prospective Payment System rule, which would increase reimbursement f...

Early Studies of Two Regimens Show Benefit in High-Risk Smoldering Multiple Myeloma
https://ascopost.com/issues/april-25-2019/regimens-show-benefit-in-high-risk-smoldering-multiple-myeloma/

Apr 24th, 2019 - MORE DATA are in to support early intervention for high-risk smoldering multiple myeloma—an early, asymptomatic entity lacking the presence of CRAB criteria (elevated calcium, renal failure, anemia, bone lesions). The latest come from two phase II studies presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, which built upon the backbone of lenalidomide plus de...

New Model May Improve Prediction of Risk in Myelodysplastic Syndromes
https://ascopost.com/issues/april-25-2019/new-model-may-improve-prediction-of-risk-in-myelodysplastic-syndromes/

Apr 24th, 2019 - A PERSONALIZED risk-prediction model for myelodysplastic syndromes (MDS) has been developed through the use of a machine-learning approach that analyzes genomic and clinical data for an individual patient. According to lead investigator Aziz Nazha, MD, of the Cleveland Clinic, the model provides survival estimates at different time points, predicts for transformation, and outperforms current mo...

Expert Point of View: High-Risk Smoldering Multiple Myeloma
https://ascopost.com/issues/april-25-2019/epov-smoldering-myeloma/

Apr 24th, 2019 - IN SPITE of the high response rates and lack of progression to active disease with the regimens described at the 2018 American Society of Hematology Meeting & Exposition, several myeloma experts interviewed by The ASCO Post said the data do not yet move them to routinely intervene in high-risk smoldering disease, largely because the studies are small and lack controls. Several experts also poin...

Robert A. Kyle, MD, Luminary in Myeloma Research: Journey From a One-Room Schoolhouse to Groundbreaking Research
https://ascopost.com/issues/april-25-2019/robert-kyle-luminary-in-myeloma-research/

Apr 24th, 2019 - Jame Abraham, MD, FACP In this installment of Living a Full Life, guest editor Jame Abraham, MD, FACP, interviewed multiple myeloma pioneer Robert A. Kyle, MD, whose groundbreaking work has changed the practice of hematology. Among his many honors are the David A. Karnofsky Memorial Award from ASCO and the Wallace H. Coulter Award from the American Society of Hematology. They are the highest ho...

Emerging translational science discoveries, clonal approaches, and treatment trends in ...
https://doi.org/10.1002/hon.2622
Hematological Oncology REFERENCES; Mughal TI, Pemmaraju N et. al.

Apr 23rd, 2019 - The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on December 4 and 5, 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in th...

CDC: Opioids OK for People With Cancer and Sickle Cell Disease
https://www.ashclinicalnews.org/online-exclusives/cdc-opioids-okay-people-cancer-sickle-cell-disease/

Apr 18th, 2019 - The Centers for Disease Control and Prevention (CDC) has clarified its 2016 guidelines for opioid prescription, stating that the recommendations were not intended to deny the pain medications to patients with cancer- or sickle cell disease–related pain. Three years ago, the CDC issued the guidelines in response to the growing opioid epidemic; it asked primary-care clinicians to rein in prescrip...

ASCO/ASH Offer Guidance on Anti-Anemia Drugs
https://www.medpagetoday.com/hematologyoncology/hematology/79297

Apr 17th, 2019 - Patients with chemotherapy-associated anemia and whose cancer treatment is not curative in intent may receive erythropoiesis-stimulating agents (ESAs) to raise serum hemoglobin (HgB) to ≥10 mg/dL, according to an updated clinical guideline. Red blood cell (RBC) transfusion also is an option for such patients, as recommended by a panel representing the American Society of Clinical Oncology (ASCO...

ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents
https://ascopost.com/News/59951

Apr 16th, 2019 - ASCO and the American Society of Hematology (ASH) have released an update to existing guidelines for the use of erythropoiesis-stimulating agents to manage anemia in patients with cancer. The update was simultaneously published in the Journal of Clinical Oncology and Blood Advances. “The current update aims to increase awareness of recent developments regarding the use of erythropoiesis-stimula...

ASCO/ASH Clinical Practice Update: Erythropoiesis-stimulating agents
https://www.mdedge.com/hematology-oncology/article/198888/patient-survivor-care/asco/ash-clinical-practice-update?channel=39313
Caleb Rans

Apr 15th, 2019 - Erythropoiesis-stimulating agents (ESAs) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin (HgB) has declined to less than 10 g/dL, according to a clinical practice guideline update by the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH). Furthermore, ESAs should not be offere.

CDC clarifies opioid prescribing guidelines in cancer, sickle cell disease
https://www.mdedge.com/hematology-oncology/article/198865/patient-survivor-care/cdc-clarifies-opioid-prescribing-guidelines?channel=39313
Alicia Gallegos

Apr 15th, 2019 - Officials at the Centers for Disease Control and Prevention have clarified the agency’s guidelines on opioid prescribing after a trio of organizations raised concerns that insurers were inappropriately applying the recommendations to active cancer patients when making coverage determinations. Dr.

FDA Pipeline: Designation in Uveal Melanoma, Application for MDS Side-Effect Management
https://ascopost.com/News/59933

Apr 11th, 2019 - Over the past week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for metastatic uveal melanoma and received a biologics application for an agent to control anemia. Fast Track Designation for Tebentafusp in Metastatic Uveal Melanoma The FDA granted Fast Track designation for tebentafusp in the treatment of patients who are HLA-A*0201–positive with p...

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482353
Blood Advances; Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ES...

Venetoclax in the treatment of chronic lymphocytic leukemia.
https://doi.org/10.1080/17425255.2019.1606211
Expert Opinion on Drug Metabolism & Toxicology; Korycka-Wolowiec A, Wolowiec D et. al.

Apr 10th, 2019 - Venetoclax, an antagonist of BCL-2 protein plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). It has been approved by the FDA for the treatment of relapsed/refractory CLL with del17p, and by the EMA for patients with del17p/TP53 mutation who have failed a BCR inhibitor, or in patients without those aberrations who have failed previous therapy, regardless of their...

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Bohlius J, Bohlke K et. al.

Apr 10th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ES...

Allogeneic Hematopoietic Cell Transplantation and Cell Therapy
https://ascopost.com/issues/april-10-2019/allogeneic-hematopoietic-cell-transplantation-and-cell-therapy/

Apr 9th, 2019 - Syed Ali Abutalib, MD Navneet Majhail, MD, MS As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several studies of allogeneic hematopoietic cell transplantation (allo-HCT) and cellular therapy, as used in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (C...

CDC Clarifies Opioid Prescribing Guideline
https://www.medpagetoday.com/painmanagement/opioids/79111?comment=true

Apr 9th, 2019 - ATLANTA -- Clinicians who prescribe opioids to control chronic pain in cancer patients, palliative care, and end-of-life care should follow recommendations of clinical practice guidelines specific to the settings, according to the CDC. Pain management in cancer, palliative care, and end-of-life care involves "unique therapeutic goals and balance of risks and benefits with opioid therapy," Debor...

CDC Clarifies Opioid Prescribing Guideline
https://www.medpagetoday.com/painmanagement/opioids/79111

Apr 9th, 2019 - ATLANTA -- Clinicians who prescribe opioids to control chronic pain in cancer patients, palliative care, and end-of-life care should follow recommendations of clinical practice guidelines specific to the settings, according to the CDC. Pain management in cancer, palliative care, and end-of-life care involves "unique therapeutic goals and balance of risks and benefits with opioid therapy," Debor...

CDC Clarifies: Okay to Prescribe Opioids for Cancer Pain
https://www.staging.medscape.com/viewarticle/911552

Apr 8th, 2019 - The Centers for Disease Control and Prevention (CDC) has issued a clarification letter that states the agency does not want to deny clinically appropriate opioid therapy to cancer and sickle cell disease patients, particularly those who are undergoing cancer treatment and survivors with chronic pain. The unusual issuance was addressed to three major cancer organizations who met with the CDC las...

CDC Clarifies: Okay to Prescribe Opioids for Cancer Pain
https://www.medscape.com/viewarticle/911552

Apr 8th, 2019 - The Centers for Disease Control and Prevention (CDC) has issued a clarification letter that states the agency does not want to deny clinically appropriate opioid therapy to cancer and sickle cell disease patients, particularly those who are undergoing cancer treatment and survivors with chronic pain. The unusual issuance was addressed to three major cancer organizations who met with the CDC las...

CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain in Patients With Cancer and Sickle Cell Disease
https://ascopost.com/News/59920

Apr 8th, 2019 - ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) are pleased to acknowledge receipt of a key clarification from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. The clarification regarding CDC’s Guideline for Prescribing Opioids for Chronic Pain—issued in a letter from the ag...

Less-Intensive Therapy Impresses in AML
https://www.medpagetoday.com/hematologyoncology/leukemia/79061

Apr 5th, 2019 - More than half of older patients with untreated acute myeloid leukemia (AML) had rapid attainment of complete remission with the combination of venetoclax (Venclexta) and low-dose cytarabine, data from a single-arm clinical trial showed. The regimen led to complete remission with or without blood-count recovery in 44 of 82 patients, with a median time to first response of 1.4 months. The cohort...

Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows
https://www.staging.medscape.com/viewarticle/911199

Apr 1st, 2019 - GLASGOW — Immune thrombocytopenia (ITP) patients in the UK are not being given intravenous immunoglobulin (IVIg) in line with current recommendations, potentially exposing them to risks, showed researchers in a novel form of audit presented at the British Society for Haematology (BSH) Annual Scientific Meeting. Immune thrombocytopenia patients in the UK have traditionally been given IVIg either...

Remembering Francesco Lo Coco, NYU Langone Health to Establish Center for Blood Cancers, and more
https://www.ashclinicalnews.org/news/the-society-pages/remembering-francesco-lo-coco-nyu-langone-health-establish-center-blood-cancers/

Apr 1st, 2019 - Remembering Francesco Lo Coco (1955 – 2019)  Francesco Lo Coco, MD, a renowned leukemia researcher and pioneer of targeted therapy, passed away on March 3, 2019. Members of the hematology community expressed shock and intense grief over this sudden loss. Dr. Lo Coco was born in Palermo, Italy. After earning his medical degree from the University of Pisa and completing his hematology training at...

ASH Expands Global Initiative, Awards Research Award to Minority Scholar
https://www.ashclinicalnews.org/news/ash-expands-global-initiative-research-award-hematologists-outside-north-america/

Apr 1st, 2019 - ASH Expands Global Initiative With Research Award for Hematologists Outside North America  The American Society of Hematology (ASH) Global Research Award was established in 2018 as part of the Society’s expanding global initiative to support the study of hematology and improve the quality of care outside of North America. The first eight winners, representing seven countries, were honored for t...

Impact of Benign Hematology Didactic Lectures on In-service Exam in a Hematology-Oncolo...
https://doi.org/10.1007/s13187-019-01515-4
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education; Lim MY, Greenberg CS

Mar 28th, 2019 - It remains unclear on whether the traditional formal didactic lecture sessions improve knowledge acquisition with conflicting data in the literature. This study evaluates the impact of an additional benign hematology didactic curriculum on the American Society of Hematology In-Service Exam (ASHISE). During the first 5 years of the study (2012-2016), formal didactic lectures consisted of medical...

ASH Reports Show Benefit of Adding Daratumumab to Initial Therapy in Multiple Myeloma
https://ascopost.com/issues/march-25-2019/benefit-of-adding-daratumumab-to-initial-therapy-in-multiple-myeloma/

Mar 24th, 2019 - Kenneth Shain, MD, PhD DARATUMUMAB APPEARS to be the “gift that keeps on giving” to the myeloma community. “It seems we can add daratumumab to almost anything and make the regimen better. It’s got good activity and a good safety profile,” said Kenneth Shain, MD, PhD, Director of the Myeloma Working Group at Moffitt Cancer Center, Tampa, who commented on the benefit observed by adding the monocl...

Maintenance Ixazomib Delays Disease Progression in Newly Diagnosed Myeloma
https://ascopost.com/issues/march-25-2019/maintenance-ixazomib-delays-disease-progression-in-newly-diagnosed-myeloma/

Mar 24th, 2019 - IN PATIENTS with newly diagnosed multiple myeloma who responded well to induction therapy and underwent transplant, 2 years of maintenance therapy with ixazomib led to a 38% improvement in progression-free survival compared with placebo, according to the results of the phase III TOURMALINE-MM3 trial, presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Meleti...

Proposed 2020 Budget Would Slash Cancer Funding
https://www.ashclinicalnews.org/online-exclusives/proposed-2020-budget-slash-cancer-funding/

Mar 22nd, 2019 - On March 11, President Donald Trump released his proposed fiscal year 2020 budget, which included a 12-percent cut to the U.S. Department of Health and Human Services (HHS) funding. That entails a $4.7 billion decrease in funding for the National Institutes of Health (NIH) – the U.S.’s largest provider of funding for biomedical research. The administration’s “A Budget for a Better America” also...

Update on Newer Treatments in Non-Hodgkin Lymphomas
https://ascopost.com/issues/march-10-2019/update-on-newer-treatments-in-non-hodgkin-lymphomas/

Mar 9th, 2019 - Syed Ali Abutalib, MD Matthew Lunning, DO AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas (NHLs), including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and CD30-positive periph...

Roy L. Silverstein, MD, Begins Term as 2019 ASH President
https://ascopost.com/issues/march-10-2019/roy-silverstein-begins-term-as-2019-ash-president/

Mar 9th, 2019 - ROY L. SILVERSTEIN, MD, an expert in platelet and vascular cell biology, as well as clinical nonmalignant hematology and thrombosis, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2019. Roy L. Silverstein, MD Dr. Silverstein is Chairman of the Department of Medicine at the Medical College of Wisconsin (MCW) in Milwaukee, where he also serv...

ASH President Roy Silverstein, MD, Issues Comment on Maintenance of Certification Recommendations Draft
https://ascopost.com/issues/march-10-2019/roy-silverstein-issues-comment-on-moc-recommendations-draft/

Mar 9th, 2019 - RECENTLY, THE American Society of Hematology (ASH) submitted feedback on draft recommendations for reforming Maintenance of Certification (MOC) to a commission appointed by the American Board of Medical Specialties (ABMS) and other entities. The “Vision Commission” released a report of its draft recommendations for reforming continuing board certification in December. ASH submitted comments on ...

Advances in Haploidentical Transplantation and Cellular Therapies
https://ascopost.com/issues/march-10-2019/advances-in-haploidentical-transplantation-and-cellular-therapies/

Mar 9th, 2019 - With advances in the field, the number of haploidentical stem cell transplants being performed (ie, using human leukocyte antigen [HLA] half-matched donor stem cells) has been increasing. In recognition of evolving strategies to improve outcomes, a group of transplant physicians started the Haploidentical Transplant Symposium (HAPLO) in 2012. Physicians and researchers continue to meet annually...

Priority review granted to lenalidomide for FL, MZL
https://www.mdedge.com/hematology-oncology/article/195481/b-cell-lymphoma/priority-review-granted-lenalidomide-fl-mzl?channel=59374
Jennifer Smith

Mar 2nd, 2019 - The Food and Drug Administration has granted priority review to a supplemental new drug application (sNDA) for lenalidomide (Revlimid). Celgene is seeking approval for lenalidomide in combination with rituximab to treat patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Congress Passes Bipartisan Sickle Cell Bill
https://www.ashclinicalnews.org/news/congress-passes-bipartisan-sickle-cell-bill/

Mar 1st, 2019 - The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation designed to improve the lives of patients living with sickle cell disease (SCD). The act includes provisions for the following: authorizing public health initiatives in SCD authorizing a SCD surveillance and data coll...

Avatrombopag for the treatment of immune thrombocytopenia.
https://doi.org/10.1080/1744666X.2019.1587294
Expert Review of Clinical Immunology; Długosz-Danecka M, Zdziarska J et. al.

Feb 25th, 2019 - Thrombopoietin-receptor agonists (TPO-RAs) are the only American Society of Hematology (ASH) guideline-advocated, second-line treatment for immune thrombocytopenia (ITP) that have been validated by randomized, controlled trials with a placebo comparator. Avatrombopag is a new candidate in this class that has been investigated as a treatment option for the treatment of ITP. Areas covered: In thi...

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML
https://www.mdedge.com/hematology-oncology/article/195043/transplantation/midostaurin-maintenance-may-reduce-relapse-risk/page/0/1?channel=50521

Feb 25th, 2019 - Studies are increasingly suggesting that posttransplant maintenance therapy may improve this outcome. For example, the small, randomized, phase 2 SORMAIN study presented at the 2018 annual meeting of the American Society of Hematology showed a signal for benefit with posttransplant maintenance with the TKI sorafenib.